Angelo Raggioli

Angelo Raggioli is currently serving as Head of the Technology Development Unit at ReiThera, where he is leading a team of 5 people working on cell line development and viral vector engineering, both for internal research and external customers. 

He is experienced in the field of Genetic Vaccines and Cell and Gene Therapy, with a strong focus on Adenoviruses and Adeno-Associated Viruses (AAV). Before joining ReiThera, Angelo worked as Lab Manager within the Neurobiology Team at the European Molecular Biology Laboratory (EMBL, Italy) where he was instrumental in setting up AAV production and purification protocols. 

Angelo holds a PhD in Molecular Embryology (Freiburg, Germany), following training in Medical Biotechnology (BSc and MSc in Naples, Italy). Angelo authored 11 scientific publications in international peer reviewed journals, covering various topics including the clinical deployment of a novel gorilla adenovirus-based vaccine against SARS-COV2.